CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca Plc’s experimental breast cancer pill delayed disease progression by over six months, according to data from a ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...